MBX Biosciences, Inc. (MBX) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

High Risk
Significant dilution risk
Last updated: May 07, 2026

Risk Assessment Details

Potential Dilution: 76.33% of current shares
Recent Dilution: 51.48% (2 years)
Historical Dilution Factor: significant recent dilution
Outstanding Shares
47M
Potential Supply
36M
Additional shares possible
Splits
None
Past 2 years

Summary

MBX currently has 46.6M outstanding shares. with significant dilution risk as 35.5M authorized shares could dilute existing holders by 76.3%. The company has significantly diluted shareholders by 51.48% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 07, 2026

10-Q filing | 46.6M shares outstanding

47M 36M
Mar 12, 2026

10-K filing | 47.5M shares outstanding

48M 36M
Nov 06, 2025

S-3 filing: The company may offer and sell up to $400,000,000 in aggregate principal amount of any combination of common stock, preferred stock, or debt securities.

45M 36M
Nov 06, 2025

10-Q filing | 44.9M shares outstanding

45M 28M
Sep 26, 2025

8-K filing: MBX Biosciences, Inc. completed a public offering of 11,108,055 shares of common stock at $18.00 per share, resulting in net proceeds of approximately $187.5 million. ($187.5M proceeds)

33M 28M
Sep 22, 2025

S-1 filing: The company is offering 10,000,000 shares of common stock in an S-1 filing.

33M 28M
May 12, 2025

10-Q filing | 33.4M shares outstanding

33M 18M
Mar 17, 2025

10-K filing | 33.4M shares outstanding

33M 18M
Nov 07, 2024

10-Q filing | 33.4M shares outstanding

33M 18M
Sep 09, 2024

S-1/A filing: This S-1/A filing relates to an offering of common stock, with underwriters having an option to purchase additional shares. The company intends to list its common stock on the Nasdaq Global Select Market under the symbol “MBX.”

30M 18M
Aug 30, 2024

S-1/A filing: S-1/A filing for common stock offering with J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities as underwriters.

260M 0
Aug 23, 2024

S-1 filing: This S-1 filing is for an initial public offering of common stock, with J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities acting as underwriters. The company has applied to list its common stock on the Nasdaq Global Select Market under the symbol 'MBX'.

260M 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime